Abstract
AbstractEvidence of increasing prevalence of amphetamine mis‐use, with a concomitant increase in intravenous administration of the drug, highlights the need for better alternatives to the current pharmacological interventions available for the treatment of amphetamine withdrawal symptoms, and prevention of relapse. A number of amphetamine analogues are neurotoxic to serotonergic neural pathways. In addition, there is evidence of reduced activity in serotonergic pathways in individuals with antisocial personality disorder and substance abuse. We report on the use of fluoxetine in eight cases of whom four achieved abstinence. Three cases reported a reduction in amphetamine use and only one reported no change in the level of use. Control studies are indicated and the use of fluoxetine in relapse prevention warrants further investigation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Human Psychopharmacology: Clinical and Experimental
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
